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ABSTRACT
Introduction Performing contractions with minimum 
force fluctuations is essential for everyday life as 
reduced force steadiness impacts on the precision of 
voluntary movements and functional ability. Several 
studies have investigated the effect of experimental or 
clinical musculoskeletal pain on force steadiness but with 
conflicting findings. The aim of this systematic review is 
to summarise the current literature to determine whether 
pain, whether it be clinical or experimental, influences 
force steadiness.
Methods and analysis This protocol for a systematic 
review was informed and reported in line with the 
Preferred Reporting Items for Systematic Reviews and 
Meta- Analyses Protocols and the Cochrane Handbook for 
Systematic Reviews of Interventions. Key databases will 
be searched from inception to 31 August 2020, including 
MEDLINE, EMBASE, PubMed, CINAHL Plus, ZETOC and 
Web of Science. Grey literature and key journals will be 
also reviewed. Risk of bias will be assessed with the 
Newcastle- Ottawa tool, and the quality of the cumulative 
evidence assessed with the Grading of Recommendations, 
Assessment, Development and Evaluation guidelines. If 
homogeneity exists between groups of studies, meta- 
analysis will be conducted. Otherwise, a narrative 
synthesis approach and a vote- counting method will be 
used, while the results will be presented as net increases 
or decreases of force steadiness.
Ethics and dissemination The findings will be presented 
at conferences and the review will be also submitted for 
publication in a refereed journal. No ethical approval was 
required.
PROSPERO registration number CRD42020196479
INTRODUCTION
During a voluntary movement of submaximal 
effort, the force produced by an individual 
is not constant, instead, it fluctuates around 
an average value.1 This variability of force is 
the consequence of neuromuscular noise and 
other environmental influences.2 The ability 
of an individual to produce a steady force 
during a submaximal voluntary contraction is 
defined as force steadiness (or torque steadi-
ness) and is an important aspect of force 
control.3 Being able to perform contractions 
with minimum force fluctuations is essen-
tial for physical function and its impairment 
could influence the precision of voluntary 
movements. This could affect the joints’ 
dynamic stability, coordination and poten-
tially result in altered joint kinematics and 
overall function.4–8
Smooth force generation is highly depen-
dent on the sense of force, which is part of 
proprioception.9 Multiple neuromuscular 
receptors, including Golgi tendon organs, 
muscle spindles (proprioceptors) and 
pressure- sensitive skin receptors contribute 
to the perception of force, by detecting 
mechanical tissue changes and transmit-
ting action potentials to the central nervous 
system (CNS).10 The proprioceptive infor-
mation (afferent inflow) from these recep-
tors enters the spinal cord dorsal horn and 
then ascends via the dorsal column medial 
lemniscus pathway to the cerebral cortex 
(conscious path) or via the spinocerebellar 
pathways to the cerebellum (unconscious 
path).11 Processing of proprioceptive afferent 
information can occur at all levels of the 
CNS, while it is consciously appreciated in the 
primary somatosensory area of the cerebral 
cortex.11 In this area, proprioceptive informa-
tion is integrated with other somatosensory, 
vestibular and visual information.11 Then, 
a descending cerebral (efferent) motor 
command is sent to the tissues involved, 
resulting in an appropriate action.9 For this 
interactive and complex process, continuous 
monitoring and modulation of ascending and 
descending information is required, based on 
Strengths and limitations of this study
 ► This will be the first systematic review to synthesise 
evidence and examine the effect of experimental 
and/or clinical pain on force steadiness.
 ► The effect of experimental or clinical pain on force 
steadiness will be considered for a wide range of 
joints and muscles during different contraction types 
of varying force.
 ► This protocol was written in accordance with 
the recommendations provided by the Cochrane 
Handbook for Systematic Reviews of Interventions.
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the proprioceptive input, motor output, perception and 
the resulting action.9 Therefore, proprioception is of vital 
importance in force control and proprioceptive deficits 
could possibly severely impair an individual’s ability to 
maintain a steady force.12 Assessment of force steadiness 
is one way to evaluate sense of force and it is usually quan-
tified either in absolute terms as the standard deviation 
(SD) of the force (or torque) signal or in relative terms as 
the coefficient of variation (CoV) over time.13–15 Higher 
values of both SD and CoV represent poorer control of 
muscle force. During this process, visual feedback of the 
force can either be provided to the individual or not. 
Indeed, studies have shown that force steadiness can be 
influenced by the visual system.16
It is well known that pain alters the way that we move 
and that the related changes can persist even after the 
resolution of pain.17 18 Additionally, abundant research 
has shown that in the presence of acute, chronic or exper-
imentally evoked pain, proprioception is usually reduced, 
likely due to altered afferent input from the painful area 
and/or central factors.9 11 19–22 It is believed that the 
afferent information received from these receptors could 
interfere with the nociceptive input at various neuro-
physiological levels of processing (ie, cortical, spinal or 
peripheral), as both travel through a common complex 
neurological pathway and suppression of the proprio-
ceptive input by nociceptive signals could occur (in the 
periphery and/or in the somatosensory cortex and/
or during the descending proprioceptive command).9 
Additionally, disruption of musculoskeletal tissues and 
concurrent damage or destruction of mechanoreceptors 
can occur in the presence of a musculoskeletal injury 
(trauma) which could further disrupt proprioception.11
Considering the above, various studies have evaluated 
the influence of clinical or experimental pain on force 
steadiness during submaximal isometric or dynamic 
tasks. Among those, some have shown that people with 
painful musculoskeletal conditions such as neck pain23 
or patellofemoral pain syndrome24 present with reduced 
force steadiness compared with asymptomatic individuals 
during isometric neck flexion and knee extension tasks 
respectively. Others have shown that short- term experi-
mental muscle pain decreases force steadiness of upper 
and lower limb muscles during isometric contractions.25–27 
However, there are also other studies with contradicting 
results, showing no difference in force steadiness with 
experimentally induced pain within the anterior tibialis 
muscle during isometric ankle dorsi- flexion tasks28 and 
in clinical conditions such as chronic elbow pain during 
isometric wrist extensions29 and shoulder impingement 
during isometric shoulder external/internal rotations.30 
Finally, others showed that force steadiness deficits in 
people with neck, shoulder pain or knee osteoarthritis 
were apparent only during specific movements and/or 
during the exertion of high forces.13 31 32
To our knowledge, no previous report has systematically 
reviewed the available body of literature investigating the 
influence of pain on force steadiness. Thus, the aim of 
this systematic review is to summarise the current litera-
ture to determine whether pain, whether it be clinical or 
experimental, influences force steadiness.
METHODS
This systematic review protocol is reported according to 
the Cochrane Handbook for Systematic Reviews of Inter-
ventions, the Conducting Systematic Reviews and Meta- 
analyses of Observational Studies of Etiology (COSMOS- E) 
guidance and the Preferred Reporting Items for System-
atic Reviews and Meta- Analyses (PRISMA) Protocol 2015 
checklist (online supplemental file 1).33–36 The Cochrane 
Handbook mainly focuses on the synthesis of evidence 
from intervention studies which is not related to this 
systematic review, as such research question is commonly 
addressed by observational studies. However, we followed 
these guidelines in addition to the COSMOS- E guidance 
for the following reasons: First, there are many similarities 
in the general structure and procedures used in both types 
of reviews. Second, the information within the Cochrane 
Handbook is described in more detail, and contains some 
information related to observational studies and, third, 
to date, widely accepted standards of systematic reviews- 
meta- analysis of observational studies are lacking.37 We 
are aware though that methodological differences exist, 
and thus particular attention will be given to certain 
steps of the conducted process (eg, choice of statistical 
methods, sources of heterogeneity, etc).37
Eligibility criteria
The eligibility criteria for this systematic review were 
delineated according to the Population, Intervention, 
Comparison, Outcomes and Study design (table 1).35 38 
However, due to the nature of the studies that will be 
included in this review, ‘Intervention’ was rephrased to 
‘Indicator’ as done previously.39
Information sources
The following electronic databases will be searched from 
inception to 31 August 2020: MEDLINE (Ovid Inter-
face), EMBASE (Ovid Interface), PubMed, CINAHL 
Plus (EBSCO Interface), ZETOC and Web of Science 
(Clarivate Analytics). Database- specific search strategies 
have been developed and they include medical subject 
headings (MeSH) where appropriate. MeSH terms were 
included to enhance our research strategy by making it 
more efficient and better informed.40
In addition to database searching, handsearching of 
key journals will be conducted too. This will include the 
following journals: Journal of Electromyography and 
Kinesiology, Clinical Biomechanics, Muscle & Nerve, 
Journal of Orthopaedic & Sports Physical Therapy, 
Journal of Science and Medicine in Sport, Isokinetics and 
Exercise Science and Journal of Applied Physiology. Addi-
tionally, any relevant in- progress work that has not been 
published yet, will be identified by contacting relevant 
authors in the field. To minimise the risk of publication 
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bias, grey literature will be included too, and it will be 
accessed via the British national bibliography for report 
literature, OpenGrey database, ProQuest Dissertations & 
Theses Global and EThOs. The World Congress of Biome-
chanics, International Society of Biomechanics, Interna-
tional Society of Electrophysiology and Kinesiology and 
the World Confederation for Physical Therapy congresses 
will be assessed too, from 2016 to 2020. If deemed neces-
sary, the authors of potentially eligible studies will be 
contacted to check/confirm whether they had published 
their study or not. Previous systematic reviews on the 
same topic will be searched too if applicable. However, 
to our knowledge no previous systematic review exists on 
this topic. Moreover, to further minimise the risk of publi-
cation bias the reference lists of the included studies will 
be handsearched for additional relevant studies that have 
been missed with the search.41
Search strategy
The search strategy will be conducted by the lead author 
(MA) with no restrictions in terms of the date, format, 
design, region or language. To ensure that the search 
will be comprehensive and reproducible, it was devel-
oped after completion of scoping searches and with help 
provided by an experienced Health Sciences Librarian, 
member of the Research Skills Team of the University of 
Birmingham. A complete electronic search strategy for 
the MEDLINE (Ovid Interface) database can be found 
in the online supplemental file 2. This search strategy 
uses a combination of MeSH (including exploded terms) 
Table 1 Inclusion and exclusion criteria
Population Studies will be included if the population of interest is (1) adults aged ≥18 years old, with (2) musculoskeletal 
pain (clinical), that is, ‘pain experienced in muscles, tendons, bones or joints that arises from an underlying 
disease classified elsewhere’—chronic secondary musculoskeletal pain(78)or ‘pain that is characterised by 
significant emotional distress or functional disability, and cannot be attributed directly to a known disease or 
damage process’—chronic primary musculoskeletal pain(78 79)and/or (3) experimentally induced musculoskeletal 
pain, that is, musculoskeletal pain experienced due to sensitisation of nociceptors located in subcutaneous 
tissue (eg, electrical stimulation of the muscle, chemical stimulation of the muscle and/or joint)(80)and (4) a 
comparative control group of asymptomatic individuals is present or individuals are exposed to different 
condition themselves (ie, cross- over design, where participants are assessed when they do not experience 
pain, when they do and after the painful experience subsides). There will be no restrictions in terms of gender 
and/or ethnicity. Studies in which pain is evoked by exercise (delayed onset of muscle soreness) and/or muscle 
fatigue will be excluded. Studies consisting of individuals with musculoskeletal pain who have been diagnosed 
with an underlying medical pathology or disorder (eg, muscular dystrophies, neurological disorders, systemic 
inflammatory diseases) and/or previously had a surgery and/or fracture related to the area of interest, will be 
excluded. This is because the main outcome of this study is to check the effect of pain on force steadiness in 
clinical populations and we wanted to avoid the confounding effects of the surgery (ie, tissue damage, decrease 
in muscle mass) on steadiness.
Indicator Eligible studies will be those which include the use of a dynamometer or any other device (eg, force or torque 
sensors) to measure force or torque steadiness or any equivalent to those (eg, force or torque or moment 
variability). However, any studies using force platforms to measure stance steadiness (eg, while standing) will be 
excluded. Both studies that provided visual feedback of individual’s force or torque output during (at least in a 
part of) the trial or did not provide visual feedback at all, will be included. All types of contractions which were 
measured at an absolute force or torque level or any level relative to individual’s maximal voluntary contraction 
(MVC) will be included without any restriction. There will be also no restriction for the side evaluated (ie, 
dominant or non- dominant).
Comparison Eligible studies will be those which include a comparison of force or torque steadiness related to a voluntary 
contraction during a painful and a non- painful state respectively. The comparison could be within- groups 
(eg, experimentally induced pain) or between- groups (eg, pain group and control group). Additionally, the 
comparison could also include multiple and/or pre- and post- task measurements.
Outcomes The outcome of interest is the measurement of force or torque steadiness. Any measure related to force or 
torque steadiness will be included, including CoV (ie, the ratio of the SD of the force/torque signal to the mean 
force/torque exerted during the force/torque- matching task, multiplied by 100), SD, root mean square error.
(15 81 82)Only quantitative studies that measure force/torque steadiness or variability will be included. Studies 
measuring other aspects of muscle force control (eg, force accuracy) will be excluded.
Study design Based on scoping searches, observational studies mainly address this review’s research question. Therefore, in 
this systematic review only observational studies (ie, cross- sectional, case–control and cohort studies), using 
quantitative methods will be included. Non- original literature (eg, systematic and narrative reviews) or other 
types of studies will be excluded. Any risk of introduction of bias will be minimised by including studies of all 
languages in the search. However, non- English written studies will be excluded by reason of limitations such as 
time and resources. Any studies excluded, will be reported on the PRISMA flow diagram.
CoV, coefficient of variation; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta- Analyses; SD, standard deviation.
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and keyword searching, to ensure maximal retrieval.42 
Appropriate adjustments will be performed to the main 
search strategy, to fully adapt it to the other databases. 
These adjustments will include changes in terms of MeSH 
and syntax. For instance, the ADJ operator will change to 
‘NEAR’ for the Web of Science database and to ‘N’ for the 
CINAHL Plus (EBSCO Interface). However, consistency 
will be ensured at all times.
Data management
One reviewer (MA) will import all search results into 
EndNote X9 (Clarivate Analytics) reference manage-
ment software. This will include citations and abstracts of 
potentially eligible studies identified and it will allow the 
identification and removal of any duplicates, before the 
start of the screening process. Then, the full text of the 
remaining potential relevant studies will be retrieved and 
saved into the same software. The final list of the poten-
tially eligible studies (abstracts and full texts) will be saved 
in separate folders; one for each independent reviewer 
(MA and AS). Screening forms that reflect the aforemen-
tioned inclusion/exclusion criteria will be developed, 
piloted and used for the screening process.
Study selection
The screening forms will be pilot tested first by both 
reviewers on a small number of articles, to ensure their 
effectiveness. The screening process will begin with 
the screening of the titles/abstracts of the identified 
studies against the inclusion/exclusion criteria by the 
two reviewers (MA and AS) independently. Using the 
screening forms, the reviewers will subcategorise the 
studies into definitely eligible, definitely ineligible or 
doubtful.41 Therefore, any obviously irrelevant studies 
and relevant studies will be excluded and included 
respectively. In the event of doubtful categorisation, the 
reviewer will read the full text for further clarification. 
If uncertainty still exists, a meeting will be arranged 
between the two reviewers to discuss and decide whether 
this study should be included or not. If the two reviewers 
do not reach to an agreement after discussion, when 
a study’s eligibility is unclear or in any other event of 
disagreement, a third independent reviewer (EM- V) will 
mediate the process. If further information is required to 
support the screening process, the authors of the study 
will be contacted.
The two reviewers will then independently examine the 
full text of all remaining studies for compliance with the 
eligibility criteria. Again, the third reviewer will support 
the process if necessary. During both the title/abstract 
and full- text screening phases, agreement between the 
two reviewers will be assessed with the kappa (κ) statistic.43 
According to Orwin,44 fair agreement will be reflected 
in values of kappa statistic between 0.40 and 0.59, good 
agreement in values between 0.60 and 0.74 and when 
the values are ≥0.75, the agreement will be considered 
as excellent. Information regarding the excluded studies 
will be reported within the PRISMA flow diagram.
Data collection process
A data extraction form will be developed, based on the 
checklist for data collection provided by Li et al,4343 and it 
will be driven by the objective of this review and the inclu-
sion criteria. Pilot testing of this form will be performed 
on a small number of randomly chosen studies prior to 
its use; to ensure its effectiveness in collecting all the 
necessary information. MA will then extract and collate 
all the information and the accuracy of this process will 
be checked by AS. If any discrepancies exist, discussion 
between the two reviewers will be the first step to resolve 
them, but if the two reviewers do not reach to an agree-
ment, the third reviewer (EM- V) will review the discrep-
ancy. Author and/or journal details will not be concealed 
from the two reviewers.
If a study consists of ambiguous or inconclusive results, 
or any crucial information (eg, unpublished data) that 
needs to be extracted is missing, the authors will be 
contacted, and they will be asked to reply within 2 weeks. 
If the corresponding authors do not respond within the 
requested time period and further clarification is vital 
to classify a study as eligible, this study will be excluded 
under the following reason: ‘for ambiguity’. If multiple 
versions of the same study exist, they will be collated, 
and the primary authors will be contacted for further 
clarification. Similarly, if two or more potentially eligible 
studies appear to use the same sample, the authors will be 
contacted to clarify whether the results are duplicated or 
not. On both occasions, any duplicates will be removed, 
one version will be selected and justified.
Data items
Items to be extracted from the eligible studies are 
presented in table 2. If a study consists of additional 
groups outside of this reviews’ population of interest (ie, 
other than an asymptomatic control group and clinical 
pain or experimental pain group or both), these studies 
will be considered eligible but only the data from the 
groups of interest will be extracted.
Risk of bias
Two reviewers (MA and AS) will independently appraise 
the included studies for risk of bias (ROB) using the 
Newcastle- Ottawa Scale (NOS).45 Assessing primary 
studies for susceptibility to bias constitutes an essen-
tial part of the systematic review conduction process, as 
inclusion of studies with high ROB may lead to invalid 
conclusions.46 47 A large number of tools to appraise bias 
in observational epidemiological studies exist, however, 
there is no consensus among the health assessment 
groups about which one is the most appropriate to 
use.48–52 Therefore, the choice of the suitable tool is not 
straightforward.
The NOS scale is the most commonly used tool to assess 
ROB in observational studies, even though the results 
concerning its reliability and validity are mixed, showing 
in some instances lower inter- rater reliability when 
compared with other tools.47 52–55 Our decision to use this 
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tool is supported by Hootman et al53 who have previously 
suggested that the NOS tool is still the preferable tool 
to assess ROB in observational studies because (1) it has 
good to moderate reliability, (2) it is easy to implement 
and (3) it has been argued to have some degree of face 
validity across observational designs. Losilla et al47 have 
also more recently shown that the NOS tool has moderate 
to good inter- rater reliability, further supporting the 
findings of Hootman et al53 and adding short scoring 
time as an additional strength. Additionally, according 
to the recommendations of Quigley et al,52 investigators 
should select the appraisal tool based on the study design. 
Based on the results revealed from scope searching, this 
systematic review will primarily consist of cross- sectional 
studies. Therefore, an adapted version of NOS scale for 
cross- sectional studies will be used as has been done previ-
ously,56 57 since the main versions of this tool were tradi-
tionally developed to evaluate cohort and case- control 
studies. This will enable us to assess bias in the most rele-
vant components, specific to cross- sectional studies rather 
than observational study designs in general.
Using the published version of the NOS scale, studies 
are rated in three main domains by using eight items 
overall: selection (four items), comparability (one item) 
and exposure (three items).45 One star can be given for 
the first and third categories, while up to two stars can 
be awarded for comparability.45 Therefore, the NOS 
scores range from 0 to 9 with the latter representing the 
highest quality.45 In the adapted version of the NOS scale 
for cross- sectional studies we will follow the same star 
ranking system as in the published version, however the 
‘exposure’ domain of the original scale, will be modified 
to ‘outcome’.56 Modifications will be kept to minimum 
to ensure that the tool will remain close to the validated 
format. Depending on the number of stars that have been 
assigned to each study, then its quality will be converted 
to ‘good’, ‘fair’ and ‘poor’ in accordance with the Agency 
for Healthcare Research and Quality standards.39 58 The 
conversion thresholds used for this will be based on 
previous studies.59 Information regarding the scoring of 
each study and ROB will be collated and presented into 
a table in detail.
Data synthesis
The two reviewers will independently organise studies 
that are more homogeneous (clinically) in smaller groups 
according to the following factors:
 ► Type of pain (experimental or clinical, acute or 
chronic).
 ► The measurement of torque or force steadiness 
outcome (relative or absolute variability).
 ► The muscles and/or joints included in the 
measurement.
 ► Task characteristics (eg, sustained, dynamic, MVC 
target level).
 ► Feedback or no feedback.
This will take place, prior to the synthesis of the findings 
of the studies. The final decision of the subgrouping plan 
will be common between the two reviewers and any disa-
greement between the two will be resolved with discussion 
Table 2 Characteristics of included studies
Date of data extraction:
Information about data Data extracted
General study information Title
Authors
Year of publication
Study Methodology Study design
Study setting (including country)
Sample size
Individuals’ characteristics (age, gender; for both pain and control groups)
Clinical pain group characteristics (location, side, pain intensity, duration of symptoms)
Experimental pain group characteristics (method used, type of injection if applicable, location, etc)
Task information (type of contraction, level of contraction, number of repetitions, recording time, 
type of visual feedback and how were subjects exposed to it, etc)
Type of instrument used for the measurement (dynamometer, other type of force or torque 
transducer, etc)
Processing of torque or force signal (SD, CoV, etc)
Muscles or joints measured
Outcome Force or torque steadiness outcomes (between groups differences, within and between 
participants pre/post differences, differences throughout the experiment)
Times of measurement (no of repetitions performed by the participants to assess force or 
torque steadiness for each task and number of measurements, depending on the condition that 
participants were exposed to, especially in studies with a cross- over design as mentioned earlier)
Funding, declaration of 
conflict of interest
Funding information
Conflicts of interest of authors
CoV, coefficient of variation; SD, standard deviation.
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first and the third reviewer will mediate if needed. Pain 
will be regarded as chronic if it lasts longer than 3 months 
(ie, beyond normal healing time).60 Acute pain is ‘the 
physiological response and experience to noxious stimuli 
that can become pathologic, is normally sudden in onset, 
time limited (commonly less than 1 month), and moti-
vates behaviours to avoid actual or potential tissue inju-
ries’.61 62 Therefore, for the purposes of this systematic 
review, pain will be considered as acute if it lasts for less 
than 3 months.
When the included studies will be organised in the 
aforementioned subgroupings, the statistical heteroge-
neity of each subgroup will be quantified, using the I2 
statistic.63 Values of I2 lower than 50% will be considered as 
eligible for meta- analysis.64 Then, a random- effects meta- 
analysis will be performed for each subgroup, according 
to specific guidelines33 65 and the necessary data will be 
extracted (eg, estimate of effect, variance, etc). All data 
will then be transformed into a common rubric, which 
will most likely be odds ratios with 95% confidence inter-
vals since we will most likely deal with binary data (ie, 
increase or decrease of force or torque steadiness).66 The 
robustness of the results will be assessed with a sensitivity 
analysis.60 This will be achieved by investigating whether 
ROB (excluding studies that were characterised as high 
ROB) and/or missing data (excluding studies in which 
mean and/or variance values were missing) have an 
impact on the meta- analysis.65 67
However, scoping searches of the current literature 
revealed that clinical diversity (eg, variability in terms of 
population, exposure, etc) and methodological diver-
sity (eg, variability in terms of ROB) exists among the 
potentially eligible studies. Therefore, undertaking a 
meta- analysis may not be possible. In this case, a narrative 
synthesis approach will be used instead in this review and 
the synthesis process will follow specific guidelines.66 68 
More specifically, the results will be described narratively 
in text or tabular form. A vote- counting synthesis method 
will be also used, based on the direction of effect and not 
on statistical significance or subjective rules which have 
been previously shown to be problematic.66 69 Appropriate 
methods will be used to display and present the data. It is 
most likely that this will include an effect direction plot, 
which will be used to present the results of the synthesis in 
a form as the following: ‘pain increases force steadiness’, 
‘no difference’, ‘pain decreases force steadiness’.70 71 Any 
changes or additional decisions made regarding the data 
organisation and presentation at review stage though, 
based on the actual review findings, will be reported and 
justified.
Confidence in cumulative evidence
To ensure the minimisation of ROB, the guidelines 
provided by Page et al (2019)72 in combination with 
the steps that have already been described in the infor-
mation source section will be followed. Roughly, this 
will consist of a comprehensive search (including grey 
literature, protocol registers and other), attempts to 
obtain unpublished data by contacting investigators and 
identifying studies that have not been published yet by 
contacting notable authors of the field.72 If deemed neces-
sary, funnel plots will be used to determine the extent of 
the risk.72
Finally, the Grading of Recommendations Assessment, 
Development and Evaluation approach will be used to 
appraise the evidence, in terms of cumulative strength 
and quality.73 74 This will include five steps as described 
by Goldet and Howick75 and the final quality of evidence 
will be presented as ‘high’, ‘moderate’, ‘low’ or ‘very 
low’. According to these guidelines, observational studies 
will be given an a priori rating of low quality and from 
that point their quality will be either upgraded or down-
graded.75 Reasons to upgrade the certainty of evidence 
will include large effect sizes and dose–response rela-
tionships between pain and force steadiness, while ROB, 
inconsistencies between studies, imprecision, indirectness 
of evidence and publication bias will be reasons to down-
grade the certainty of evidence.76 This classification of 
the cumulative quality of evidence will be completed for 
the combined grouping for all studies within the review 
and for each subgroup of studies, as described previously. 
Based on this assessment of the evidence, recommenda-
tions for the interpretation of the evidence will be given 
as described by Guyatt et al and Dekkers et al.33 77
Patient and public involvement
This systematic review protocol was not developed 
following discussions within a patient and public involve-
ment meeting (PPI), due to COVID-19. Patients will not 
be involved in the analysis and data collection of the 
systematic review. However, the results of this study will be 
shared at PPI meetings at the University of Birmingham 
in the future.
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This systematic review will involve the collection of previ-
ously published studies, in which participants’ decision 
for participation was informed and voluntary. Therefore, 
ethical approval is not required. Our findings will be 
presented at national and/or international conferences, 
while they will also be submitted for publication in a 
refereed journal.
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